Patents by Inventor Robert M. Scarborough

Robert M. Scarborough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quaternary amidino based inhibitors of factor xa
    Publication number: 20040077690
    Abstract: Novel quaternary amidino-containing compounds of the general formulae (I), (II), (III), (IV), (V) and (VI): including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and the compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
    Type: Application
    Filed: October 16, 2003
    Publication date: April 22, 2004
    Inventors: Bing-Yan Zhu, Wenrong Huang, Penglie Zhang, Zhaozhong Jon Jia, Liang Bao, Yanhong Wu, Robert M. Scarborough
  • Inhibitors of factor Xa
    Patent number: 6720317
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: April 13, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Zhaozhong Jon Jia, Wenrong Huang, Yonghong Song, James Kanter, Robert M. Scarborough
  • Quaternary amines and related inhibitors of factor xa
    Publication number: 20040067938
    Abstract: Novel quaternary amine containing compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
    Type: Application
    Filed: November 3, 2003
    Publication date: April 8, 2004
    Inventors: Penglie Zhang, Robert M. Scarborough, Bing-Yan Zhu
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Patent number: 6693109
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: February 17, 2004
    Assignees: Eli Lilly and Company, Millennium Pharmaceuticals, Inc.
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Michael Paal, Gerd Ruhter, Kenneth J. Ruterbories, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
    Publication number: 20040029867
    Abstract: The invention relates to novel compounds of formula (I) containing benzofused heterocyclic sulfonamide derivatives which are effective platelet ADP receptor inhibitors. Such compounds including pharmaceutically acceptable salts are useful in various pharmaceutical compositions for the prevention and/or treatment of cardiovascular disease particularly those related to thrombosis.
    Type: Application
    Filed: April 9, 2003
    Publication date: February 12, 2004
    Inventors: Robert M. Scarborough, Charles K. Marlowe
  • Platelet ADP receptor inhibitors
    Patent number: 6689786
    Abstract: Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 23, 2003
    Date of Patent: February 10, 2004
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Robert M. Scarborough, Wolin Huang
  • Inhibitors of factor Xa
    Patent number: 6686368
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: February 3, 2004
    Assignee: Millennium Pahrmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Zhaozhong Jon Jia, Wenrong Huang, Yonghong Song, James Kanter, Robert M. Scarborough
  • Inhibitors of factor Xa
    Patent number: 6673817
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: May 20, 2000
    Date of Patent: January 6, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Robert M. Scarborough
  • Pharmaceutical compositions and methods using natriuretic peptides
    Publication number: 20040002458
    Abstract: The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically.
    Type: Application
    Filed: March 27, 2003
    Publication date: January 1, 2004
    Inventors: J. Jeffrey Seilhamer, John Lewicki, Robert M. Scarborough, J. Gordon Porter
  • Platelet ADP receptor inhibitors
    Patent number: 6667306
    Abstract: The invention relates to novel compounds of formula (I) containing fused heterocyclic ring systems which are effective platelet ADP receptor inhibitors: In formula (I), W is carbon or nitrogen, wherein at least one W is a carbon; and Y is nitrogen, oxygen, or sulfur. Such compounds including pharmaceutically acceptable salts are useful in various pharmaceutical compositions for the prevention and/or treatment of cardiovascular disease particularly those related to thrombosis.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: December 23, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Alan M. Laibelman, Hans-Michael Jantzen, Pamela B. Conley, Larry J. Fretto, Robert M. Scarborough
  • Inhibitors of factor Xa
    Patent number: 6638980
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: October 28, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ting Su, Bing-Yan Zhu, Kim Kane-Maguire, Robert M. Scarborough, Penglie Zhang
  • Novel indazole peptidomimetics as thrombin receptor antagonists
    Publication number: 20030199455
    Abstract: The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
    Type: Application
    Filed: March 31, 2003
    Publication date: October 23, 2003
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Anjali Pandey, Robert M. Scarborough
  • Inhibitors of factor Xa
    Patent number: 6632815
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: October 14, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Zhaozhong Jon Jia, Wenrong Huang, Yonghong Song, James Kanter, Robert M. Scarborough
  • Isoquinolone inhibitors of factor Xa
    Publication number: 20030186972
    Abstract: Novel compounds of formula I: 1
    Type: Application
    Filed: September 9, 2002
    Publication date: October 2, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Charles K. Marlowe, Wenhao Li, Ting Su, Robert M. Scarborough
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Publication number: 20030171373
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: January 29, 2003
    Publication date: September 11, 2003
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Michael Paal, Gerd Ruhter, Kenneth J. Ruterbories, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • Benzamides and related inhibitors of factor Xa
    Publication number: 20030162690
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described Compositions containing such compounds are also described The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders
    Type: Application
    Filed: April 22, 2002
    Publication date: August 28, 2003
    Applicant: COR Therapeutics, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
  • Platlet ADP receptor inhibitors
    Publication number: 20030162774
    Abstract: Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis.
    Type: Application
    Filed: January 23, 2003
    Publication date: August 28, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Robert M. Scarborough, Wolin Huang
  • Piperazine and homopiperazine compounds
    Publication number: 20030153556
    Abstract: Compounds are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis.
    Type: Application
    Filed: September 6, 2002
    Publication date: August 14, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Daniel E. Levy, Mark S. Smyth, Robert M. Scarborough
  • Subcutaneous administration of natriuretic peptide
    Patent number: 6586396
    Abstract: The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: July 1, 2003
    Assignee: Scios, Inc.
    Inventors: J. Jeffrey Seilhamer, John Lewicki, Robert M. Scarborough, J. Gordon Porter
  • Inhibitors of factor Xa
    Publication number: 20030114448
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: May 28, 2002
    Publication date: June 19, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Penglie Zhang, Bing-Yan Zhu, Wenrong Huang, Robert M. Scarborough